As of March 2025, the U.S. stock market is experiencing volatility, with the Nasdaq Composite entering correction territory amid concerns over tariffs and their potential impact on economic growth. In this climate, investors may find value in exploring penny stocks—an investment area that remains relevant despite its somewhat outdated terminology. These smaller or newer companies can offer significant opportunities when supported by strong financials, providing a blend of growth potential and stability that larger firms might overlook.

Top 10 Penny Stocks In The United States

Click here to see the full list of 750 stocks from our US Penny Stocks screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Talkspace

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Talkspace, Inc. is a virtual behavioral healthcare company operating in the United States with a market cap of $466.23 million.

Operations: The company generates its revenue primarily from its Pharmacy Services segment, which accounted for $187.59 million.

Market Cap: $466.23M

Talkspace, Inc., with a market cap of US$466.23 million, has recently become profitable and reported a net income of US$1.15 million for 2024, reversing a prior loss. The company forecasts revenue growth to reach between US$220 million and US$235 million in 2025. Talkspace is debt-free, with strong short-term assets covering its liabilities and no meaningful shareholder dilution over the past year. Its management team and board are experienced, contributing to stable weekly volatility at 9%. Analysts suggest potential stock price appreciation by 74.8%, indicating positive sentiment towards its valuation prospects in the penny stock arena.

• Click here to discover the nuances of Talkspace with our detailed analytical financial health report.
• Gain insights into Talkspace's outlook and expected performance with our report on the company's earnings estimates.

908 Devices

Simply Wall St Financial Health Rating: ★★★★★★

Overview: 908 Devices Inc. is a commercial-stage technology company that offers handheld and desktop mass spectrometry devices for analyzing unknown and invisible materials across life sciences, bioprocessing, pharma/biopharma, forensics, and related markets, with a market cap of approximately $117.35 million.

Operations: The company generates $59.63 million in revenue from its Scientific & Technical Instruments segment.

Market Cap: $117.35M

908 Devices Inc., with a market cap of US$117.35 million, is currently unprofitable and reported a significant net loss of US$19.45 million for Q4 2024, alongside a goodwill impairment of US$10.14 million. Despite this, the company forecasts revenue growth between 11% to 15% for 2025, projecting revenues from continuing operations to reach US$53 million to US$55 million. The management team and board are experienced, and the company remains debt-free with sufficient short-term assets covering liabilities. However, its stock has shown high volatility recently, which may concern risk-averse investors in the penny stock segment.

• Click here and access our complete financial health analysis report to understand the dynamics of 908 Devices.
• Evaluate 908 Devices' prospects by accessing our earnings growth report.

Expensify

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Expensify, Inc. offers a cloud-based expense management software platform catering to individuals, corporations, small and midsized businesses, and enterprises globally, with a market cap of approximately $340.05 million.

Operations: Expensify generates revenue from its Internet Software & Services segment, totaling $139.24 million.

Market Cap: $340.05M

Expensify, Inc., with a market cap of US$340.05 million, remains unprofitable but has improved its financial position by reducing net losses to US$10.06 million in 2024 from US$41.46 million the previous year. The company maintains a strong cash runway for over three years and is debt-free, providing some stability in the volatile penny stock landscape. Recent developments include launching Expensify Travel, enhancing their service offerings and potentially boosting revenue streams. However, significant insider selling may raise concerns about future prospects despite trading below estimated fair value and implementing a share repurchase program to offset dilution.

• Get an in-depth perspective on Expensify's performance by reading our balance sheet health report here.
• Assess Expensify's future earnings estimates with our detailed growth reports.

Key Takeaways

• Discover the full array of 750 US Penny Stocks right here.
• Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.
• Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.

Interested In Other Possibilities?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NasdaqCM:TALK NasdaqGM:MASS and NasdaqGS:EXFY.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com